DRTS
Alpha Tau Medical LtdNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$672.39M
P/E Ratio
—
EPS
$-0.53
Beta
1.05
52W High
$8.60
52W Low
$2.50
50-Day MA
$7.20
200-Day MA
$4.92
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Alpha Tau Medical Ltd
Alpha Tau Medical Ltd., a clinical-stage oncology therapies company, is engaged in the research, development, and commercialization of alpha-emitting radiation therapy (Alpha DaRT) for the treatment of solid cancer in Israel and the United States. The company is headquartered in Jerusalem, Israel.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-41.06M |
| Operating Margin | 0.00% |
| Return on Equity | -61.00% |
| Return on Assets | -27.60% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.88 |
| Price-to-Book | 8.32 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -4.77 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $88.01M |
| Float | $45.32M |
| % Insiders | 32.05% |
| % Institutions | 2.95% |
Historical Volatility
HV 10-Day
58.39%
HV 20-Day
48.16%
HV 30-Day
58.40%
HV 60-Day
72.09%
HV Rank
55.2%
Volatility is currently contracting
Analyst Ratings
Consensus ($9.50 target)
1
Strong Buy3
BuyData last updated: 4/14/2026